| P625 | Outcomes with first-line PD-1/PD-L1 inhibition in advanced urothelial cancer (UC): A single institution experience | Arjun V. Balar, MD; Miles Hsu, BS; Yuhe Xia; Andrea Troxel, PhD; Daniela Delbeau, RN; Kaitlyn Francese, RN; Dayna Leis, RN; Deneuve Shepherd; | Checkpoint blockade; Clinical study |
| P626 | Overcoming target-driven fratricide for CAR-T cell therapy | Eytan Breman, MSc; Benjamin Demoulin; Sophie AGAUGUE, PhD; Sebastien Mauen, PhD; Alexandre E. Michaux, PhD; Lorraine P. Springuel; Fanny Huberty; Céline Jacques-Hespel; Celine Marchand, Laboratory Technician; Jérôme Marijsse; Peter DeWaele; David E. Gilham, PhD; Valérie Steenwinckel, PhD | CAR T cells; Cytokine; Solid tumors; T cell; Targeted therapy |
| P627 | From staining to analysis: fully automated workflow for multiplexed immuno-profiling in FFPE tumor samples using UltiMapper™ reagent kits | Amanda J. Bares, PhD; Michael Murphy; Heike Boisvert, PhD; Katir K. Patel, PhD; Bonnie Phillips, PhD; Sean R. Downing, PhD; Mael Manesse, PhD | Antibody; Biomarkers; Immune contexture; Tumor microenvironment |
| P628 | High dimensional immune cell profiling with data-independent acquisition mass spectrometry | Jakob Vowinckel, PhD; Tobias Treiber; Nicholas Dupuis, PhD; Kristina Beeler; Claudia Escher | Bioinformatics; Biomarkers; Monocyte/Macrophage; NK/NK T cell; Proteomics; T cell; T cell lineages |
| P629 | Addressing immunotherapy educational needs: esults from an educational program on immunotherapy for cancer patients and caregivers | Maria B. Gonzalo; Liliana Zigo, BA; Claire Saxton, MBA; Heather Hollen, BS, MS; Julie S. Olson, PhD; Kevin Stein, PhD, FAPOS; | Adoptive immunotherapy; Immune toxicity |
| P630 | Patient-reported toxicities in lung cancer patients receiving immune checkpoint blockade | Heather Jim, PhD; Sandra S. Shaw, BS, MBA; Sarah Eisel, PhD; Aasha I. Hoogland, PhD; David LeDuc, CFRE; Adam P. Dicker, MD, PhD; | Immune toxicity; Solid tumors |
| P631 | A novel CD137/PD-L1 bispecific antibody modulates the tumour microenvironment by activating CD8⁺ T cells and results in tumour growth inhibition | Matthew A. Lakins, PhD; Jose Munoz-Olaya; Daniel Jones; Raffaella Giambalvo; Clinton M. Hall; Anne Knudsen; Neus Masque Soler, Dr; Sarka Pechouckova; Emma Goodman, BSc; Cristian Gradinaru; Alexander Koers, PhD; Sylwia Marshall; Mateusz Wydro, PhD; Francisca Wollerton; Sarah Batey; Dan Gliddon; Jacqueline F. Doody, PhD; Michael Davies; Michelle Morrow, PhD; Mihriban Tuna, PhD; Neil Brewis, PhD | Antibody; Checkpoint blockade; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P632 | A multi-omics approach to understanding the tumor microenvironment | Deepali Malhotra, PhD; Gordon Moody; Michael Surace, PhD; Jaime Rodriguez-Canales, MD; Ronald Herbst, PhD; John B. Mumm, PhD; | Antigen presenting cells; Dendritic cell; Immune contexture; Myeloid cells; MDSC; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P633 | Generation of a modular landing pad cell line for T cell receptor exchange and screening | ETHAN PATTERSON; Stacey Ward, Ph.D.; jason Gustin | CAR T cells; Gene expression; T cell |
| P634 | Precision genome editing in macrophage and CD8+ human primary T cells for immuno-therapeutics applications | Laura Daley; ETHAN PATTERSON; | CAR T cells; Gene expression; Monocyte/Macrophage; T cell; T cell lineages; Targeted therapy |
| P635 | Effectiveness and tolerance of immune checkpoint blockade in a real-world lung cancer patient population | Daniel F. Pease, MD; Michael Shyne; Shilvi Joshi; Allison Lee; Manish R. Patel, DO | Autoimmunity; Checkpoint blockade; Immune toxicity; Solid tumors |
| P636 | Evaluating the occurrence of early tumor progression (ETP) in patients with gastric cancer treated with nivolumab versus placebo | Yan Feng; Paul Nghiem, MD, PhD; Paul Nghiem, MD, PhD; Ricardo Zwirtes, MD; Dan Reshef; Greg Plautz; Narikazu Boku; Li-Tzong Chen; Yoon-Koo Kang; Akintunde Bello, PhD; Amit Roy; Jennifer Sheng; | Checkpoint blockade; Clinical study; Solid tumors |
| P637 | Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin® molecule for tumor-restricted immune activation | Nicolo Rigamonti, PhD; Anja Schlegel; Sophie Barsin, MS; Jonas Schwestermann; Jennifer Krieg; Susanne Mangold; Maria Paladino; Valérie Calabro, PhD; Victor Levitsky, MD PhD; Simon E. Plyte, PhD; Michael T. Stumpp, PhD; Clara Metz, PhD | Antigen presenting cells; B cell; Costimulation; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P638 | Comparison of immunoprofiling from whole tumor versus pathologist-selected regions of interest in tissues: a study using multiplex immunofluorescence and multispectral analysis on lung cancer | Michael Surace, PhD; Matthew Gates; Clifford C. Hoyt, MS; Jennifer Cann, PhD; Jaime Rodriguez-Canales, MD; | Immunoscore; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P639 | Tumor-associated B cells promote melanoma cell dedifferentiation and invasiveness | Anastasia Samarkina, MSc; Rajasekharan Somasundaram, PhD; Meenhard Herlyn, DVM PhD; | Angiogenesis; B cell; Inflammation; Stem cell/cancer-initiating cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P640 | hMENA is a key regulator of tumor cell-cancer associated fibroblasts dialogue via Gas6/Axl paracrine axis | sheila spada, PhD; Roberta Melchionna; Francesca Di Modugno, PhD; Mariangela Panetta; Anna Di Carlo; - Anna Maria Mileo; Isabella Sperduti; Barbara Antoniani; Rita Teresa Lawlor; Lorenzo Piemonti; Maria Grazia Diodoro; Daniel D'Andrea, Ph.D.; Paolo Visca; Michele Milella; Gian Luca Grazi; Francesco Facciolo; Emily Chen; Aldo Scarpa; Paola Nistico', MD; | Tumor microenvironment; Tumor stroma |
| P641 | Development of automated protocols for OPAL, SMIFT and ESIFT 4-color lymphocyte kits | Joe A.Vargas; Julio S. Masabanda, PhD; David A. Tacha, PhD | Antibody; Antigen presenting cells; B cell; Biomarkers; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
